SUBSCRIBE
SUBSCRIBE
Jia Jie Chen

Jia Jie Chen

Freelance opinion writer

Jia Jie Chen writes analyses focusing on drug development in the biotech and pharma industries for BioSpace. He has a doctorate degree in pharmacy and experiences ranging from biotech equity research to business intelligence analysis. Follow him on LinkedIn.

Pictured: Loaded syringe and opioids_iStock, Darwi
Drug Development
Opinion: What to Expect From an Experimental Anti-Abuse Opioid Drug
Although still in early-stage testing, Ensysce Biosciences’ formulation has demonstrated the potential to address addiction problems associated with oral oxycodone.
May 25, 2023
 · 
3 min read
 · 
Jia Jie Chen
Pictured: Sarepta sign on a brick building/courtes
Policy
Opinion: Sarepta Enters Uncharted Territory with Adcomm Approval
The extensive discussion between the FDA’s advisory committee, company representatives and other interested parties could serve as a cautionary tale to developers of future gene therapies.
May 18, 2023
 · 
3 min read
 · 
Jia Jie Chen
Pictured: A dry eye/Kryuchka Yaroslav_Adobe Stock
Drug Development
Opinion: Hope on the Horizon for Sjogren’s Syndrome
Despite multiple therapeutics approved to treat localized symptoms, there are currently no systemic therapies on the market for Sjogren’s syndrome.
May 4, 2023
 · 
3 min read
 · 
Jia Jie Chen
Pictured: Conceptual illustration of a person stan
Drug Development
Reformulated: New Takes on Parkinson’s Disease Treatments
Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.
April 14, 2023
 · 
4 min read
 · 
Jia Jie Chen
CRISPR-Cas9 genome editing enzyme, 3d illustration
Drug Development
Gene Editing Therapeutics Could Hit the Market in 2023
Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.
April 7, 2023
 · 
4 min read
 · 
Jia Jie Chen
Pictured: Two people signing contracts/Courtesy of
Deals
Top Biotech Licensing Deals of Q1 2023
There have already been several big biotech licensing deals in Q1. See inside for some of this quarter’s biggest licensing deals — from the surprising and pivotal to the lucrative and consequential.
March 29, 2023
 · 
3 min read
 · 
Jia Jie Chen
Business
Raises for Moderna, Pfizer CEOs Highlight Continuing Trend
As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well.
March 20, 2023
 · 
2 min read
 · 
Jia Jie Chen
Scientists conduct an experiment_courtesy of Getty
Immuno-Oncology Pipeline Cuts Explained
Q4 and full-year 2022 financial statements have revealed several companies slashing I-O pipelines. Here are just some of the factors at play.
March 16, 2023
 · 
1 min read
 · 
Jia Jie Chen
A Novo Nordisk flag flies in the wind/Courtesy jor
Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly
After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.
March 15, 2023
 · 
2 min read
 · 
Jia Jie Chen
Pictured: SBV sign/Courtesy Bloomberg/Getty Images
Deals
Analysis: Biotech After SVB’s Collapse
The SVB failure appears to have been caused by an underwritten public offering to raise $2.25 billion to cover security losses announced during SVB’s Q1 2023 mid-quarter update.
March 14, 2023
 · 
2 min read
 · 
Jia Jie Chen
Keytruda Unlocked: How Should Merck Proceed with Trials?
Given the successes and failures of Merck’s current Keytruda development strategy, a better multi-pronged approach may be needed to optimize current resources.
March 13, 2023
 · 
2 min read
 · 
Jia Jie Chen
Courtesy Getty Images
Drug Development
CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.
March 10, 2023
 · 
3 min read
 · 
Jia Jie Chen
Load More